<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35422180</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1-2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Prevalence of amyotrophic lateral sclerosis in the United States using established and novel methodologies, 2017.</ArticleTitle><Pagination><StartPage>108</StartPage><EndPage>116</EndPage><MedlinePgn>108-116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2022.2059380</ELocationID><Abstract><AbstractText><i>Objective</i>:To estimate the prevalence of amyotrophic lateral sclerosis (ALS) in the United States for 2017 using data from the National ALS Registry (Registry) as well as capture-recapture methodology to account for under-ascertainment. Established in 2010, the Registry collects and examines data on ALS patients in the US to better describe the epidemiology of ALS (i.e. risk factor exposures, demographics).<i>Methods:</i> The Registry compiled data from national administrative databases (from the Centers for Medicare and Medicaid Services, the Veterans Health Administration, and the Veterans Benefits Administration) and a voluntary enrollment data through a web portal (www.cdc.gov/als). To estimate the number of missing cases, capture-recapture methodology was utilized.<i>Results:</i> The Registry conservatively identified 17,800 adult persons (lower-bound estimate) who met the Registry definition of ALS for an age-adjusted prevalence of 5.5 per 100,000&#x2009;US population. Using capture-recapture methodology, we obtained a "mean case count" of 24,821 ALS cases (prevalence of 7.7 per 100,000&#x2009;U.S. population) and estimated the upper-bound estimate to be 31,843 cases (prevalence of 9.9 per 100,000&#x2009;U.S. population). The pattern of patient characteristics (e.g. age, sex, and race/ethnicity) remained unchanged from previous Registry reports. Overall, ALS was most common among whites, males, and persons aged 60-69 years. The age groups with the lowest number of cases were persons aged 18-39 years. Males had a higher prevalence than females overall and across all data sources.<i>Conclusions:</i> Existing Registry methodology, along with capture-recapture methodology, are being used to better describe the epidemiology and demographics of ALS in the US.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Punjani</LastName><ForeName>Reshma</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Moon</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Theodore</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaye</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>McKing Consulting Corporation, Atlanta, GA, USA and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Lorene M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topol</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muravov</LastName><ForeName>Oleg</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genson</LastName><ForeName>Corina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention/Agency for Toxic Substances and Disease Registry, National ALS Registry (CDC/ATSDR), Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 TS000249</GrantID><Acronym>TS</Acronym><Agency>ATSDR CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="N">Medicare</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2017</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">United States</Keyword><Keyword MajorTopicYN="N">capture&#x2013;recapture</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">models</Keyword><Keyword MajorTopicYN="N">prevalence</Keyword><Keyword MajorTopicYN="N">risk</Keyword></KeywordList><CoiStatement>Declaration of interest. The CDC/ATSDR authors have no declarations of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>19</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35422180</ArticleId><ArticleId IdType="mid">NIHMS1799329</ArticleId><ArticleId IdType="pmc">PMC9568617</ArticleId><ArticleId IdType="doi">10.1080/21678421.2022.2059380</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mitsumoto H Amyotrophic lateral sclerosis. Philadelphia (PA): FA Davis Company; 1998.</Citation></Reference><Reference><Citation>Bello-Haas VD. Physical therapy for individuals with amyotrophic lateral sclerosis: current insights. Degener Neurol Neuromuscul Dis. 2018;8:45&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065609</ArticleId><ArticleId IdType="pubmed">30890895</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016; 138:225&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">27637961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Centers for Disease Control and Prevention (CDC), et al. Prevalence of amyotrophic lateral sclerosis &#x2013; United States. MMWR Suppl. 2014;63:1&#x2013;2011.</Citation><ArticleIdList><ArticleId IdType="pubmed">25054277</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis &#x2013; United States, 2012&#x2013;2013. MMWR Surveill Summ. 2016; 65:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of ayotrophic lateral sclerosis &#x2013; United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis &#x2013; United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858037</ArticleId><ArticleId IdType="pubmed">29470458</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Raymond J, Punjani R, Larson T, Bove F, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2021;0:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34423697</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaldivar T, Gutierrez J, Lara G, Carbonara M, Logroscino G, Hardiman O. Reduced frequency of ALS in an ethnically mixed population: a population-based mortality study. Neurology 2009;72:1640&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">19433736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc). 2018;54:349&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">29998226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018;17:385&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrew AS, Chen CY, Caller TA, Tandan R, Henegan PL, Jackson BP, et al. Toenail mercury levels are associated with amyotrophic lateral sclerosis risk. Muscle Nerve. 2018;58:36&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6034986</ArticleId><ArticleId IdType="pubmed">29314106</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley WG, Borenstein AR, Nelson LM, Codd GA, Rosen BH, Stommel EW, et al. Is exposure to cyanobacteria an environmental risk factor for amyotrophic lateral sclerosis and other neurodegenerative diseases? Amyotroph Lateral Scler Frontotemporal Degener. 2013; 14:325&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">23286757</ArticleId></ArticleIdList></Reference><Reference><Citation>Capozzella A, Sacco C, Chighine A, Loreti B, Scala B, Casale T, et al. Work related etiology of amyotrophic lateral sclerosis (ALS): a meta-analysis. Ann Ig. 2014;26: 456&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">25405377</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox PA, Richer R, Metcalf JS, Banack SA, Codd GA, Bradley WG. Cyanobacteria and BMAA exposure from desert dust: a possible link to sporadic ALS among Gulf War veterans. Amyotroph Lateral Scler. 2009;10(Suppl 2): 109&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">19929742</ArticleId></ArticleIdList></Reference><Reference><Citation>Goutman SA, Boss J, Patterson A, Mukherjee B, Batterman S, Feldman EL. High plasma concentrations of organic pollutants negatively impact survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:907&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6625908</ArticleId><ArticleId IdType="pubmed">30760645</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisskopf MG, Cudkowicz ME, Johnson N. Military service and amyotrophic lateral sclerosis in a population-based cohort. Epidemiology 2015;26:831&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4604116</ArticleId><ArticleId IdType="pubmed">26414854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzoni V, Pansarasa O, Diamanti L, Nosari G, Cereda C, Ceroni M. Amyotrophic lateral sclerosis and environmental factors. Funct Neurol. 2016;31:7&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4819821</ArticleId><ArticleId IdType="pubmed">27027889</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen A Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995;18:741&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7783764</ArticleId></ArticleIdList></Reference><Reference><Citation>Su FC, Goutman SA, Chernyak S, Mukherjee B, Callaghan BC, Batterman S, et al. Association of environmental toxins with amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:803&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5032145</ArticleId><ArticleId IdType="pubmed">27159543</ArticleId></ArticleIdList></Reference><Reference><Citation>US Public Health Service. ALS Registry Act. Washington, DC: 110th Congress; 2008.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. National Notifiable Diseases Surveillance System, Weekly Tables of Infectious Disease Data. Atlanta, GA. Available from: https://www.cdc.gov/nndss/infectious-tables.html.</Citation></Reference><Reference><Citation>Massachusetts Department of Public Health. Massachusetts ALS Registry. Available from: https://www.mass.gov/als-registry.</Citation></Reference><Reference><Citation>Kaye WE, Sanchez M, Wu J. Feasibility of creating a National ALS Registry using administrative data in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:433&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4587982</ArticleId><ArticleId IdType="pubmed">24597459</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Census Bureau. National Population by Characteristics: 2010&#x2013;2019. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-detail.html.</Citation></Reference><Reference><Citation>Hook EB, Regal RR. The value of capture&#x2013;recapture methods even for apparent exhaustive surveys. The need for adjustment for source of ascertainment intersection in attempted complete prevalence studies. Am J Epidemiol. 1992;135:1060&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">1534441</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou S, Qian S, Li X, Zheng L, Chang W, Wang L. Using the capture-recapture method to estimate the incidence of amyotrophic lateral sclerosis in Beijing, China. Neuroepidemiology 2018;50:29&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29324454</ArticleId></ArticleIdList></Reference><Reference><Citation>Huisman MH, de Jong SW, van Doormaal PT, Weinreich SS, Schelhaas HJ, van der Kooi AJ, et al. Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry. 2011;82:1165&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">21622937</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A, Peter RS, Erhardt S, Lul&#xe9; D, Rothenbacher D, Ludolph AC, ALS Registry Study Group, et al. Epidemiology of amyotrophic lateral sclerosis in Southern Germany. J Neurol. 2017;264:749&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">28220290</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson LM, Topol B, Kaye W, Raymond J, Horton DK, Mehta P, et al. Evaluation of the completeness of ALS Case Ascertainment in the U.S. National ALS Registry: application of the capture-recapture method. Neuroepidemiology 2021;0:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">34929703</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicare Resources. Understanding your Medicare Plan Options. Accessed
November 12, 2020. Available from: https://www.medicareresources.org/medicare-benefits.</Citation></Reference><Reference><Citation>ALS Association. VA Provides Benefits to Veterans with ALS and Families. Accessed
November 12, 2020. Available from: http://web.alsa.org/site/PageServer?pagename=va_provides_benefits.</Citation></Reference><Reference><Citation>Fombonne E Epidemiology of pervasive developmental disorders. Pediatr Res. 2009;65:591&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19218885</ArticleId></ArticleIdList></Reference><Reference><Citation>King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J Epidemiol. 2009;38:1224&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2800781</ArticleId><ArticleId IdType="pubmed">19737791</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaye WE, Wagner L, Wu R, Mehta P. Evaluating the completeness of the national ALS registry, United States. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19:112&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815913</ArticleId><ArticleId IdType="pubmed">29020837</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018; 19:126&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5815888</ArticleId><ArticleId IdType="pubmed">29262737</ArticleId></ArticleIdList></Reference><Reference><Citation>Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J Multidiscip Healthc. 2017; 10:205&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446964</ArticleId><ArticleId IdType="pubmed">28579792</ArticleId></ArticleIdList></Reference><Reference><Citation>Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014;50:4&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433000</ArticleId><ArticleId IdType="pubmed">24510737</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. Rev Neurol (Paris). 2017; 173:288&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">28461024</ArticleId></ArticleIdList></Reference><Reference><Citation>Insurance Information Institute. Facts+Statistics: Industry Overview. Available from: https://www.iii.org/fact-statistic/facts-statistics-industry-overview.</Citation></Reference><Reference><Citation>ALS Association. FYI: A Professional&#x2019;s Guide to Assisting Families with Obtaining Government Benefits. Available from: https://www.als.org/navigating-als/resources/fyi-professionals-guide-assisting-families-obtaining-government-benefits.</Citation></Reference><Reference><Citation>IQVIA Human Data Science. IQVIA PharMetrics Plus. Accessed
November 12, 2020. Available from: https://www.iqvia.com.</Citation></Reference><Reference><Citation>Optum Health Services Innovation Company. Accessed
November 12, 2020. Available from: https://www.optum.com.</Citation></Reference><Reference><Citation>Truven Marketscan Research Data. Accessed
November 12, 2020. Available from: https://marketscan.truvenhealth.com/marketscanportal/.</Citation></Reference><Reference><Citation>Irish Motor Neurone Disease Register. Available from: https://www.hiqa.ie/areas-we-work/health-information/data-collections/irish-motor-neurone-disease-register.</Citation></Reference><Reference><Citation>Gomeni R, Fava M, Pooled Resource Open-Access ALS Clinical Trials Consortium. Pooled Resource Open-Access ALSCTC. Amyotrophic lateral sclerosis disease progression model. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:119&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">24070404</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2020;7:1103&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7359115</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. HIV Surveillance Report. Accessed
November 12, 2020. Available from: https://www.cdc.gov/hiv/statistics/overview/index.html.</Citation></Reference><Reference><Citation>Yelk Woodruff RS, Pratt RH, Armstrong LR. The US National Tuberculosis Surveillance System: a descriptive assessment of the completeness and consistency of data reported from 2008 to 2012. JMIR Public Health Surveill. 2015;1:e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4869229</ArticleId><ArticleId IdType="pubmed">27227133</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>